Victory Capital Management Inc. Has $6.44 Million Position in DaVita Inc. (NYSE:DVA)

Victory Capital Management Inc. cut its holdings in DaVita Inc. (NYSE:DVA) by 56.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 39,263 shares of the company’s stock after selling 51,093 shares during the quarter. Victory Capital Management Inc.’s holdings in DaVita were worth $6,436,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of DVA. Harvard Management Co. Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at approximately $55,115,000. Lazard Asset Management LLC grew its position in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after purchasing an additional 153,008 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of DaVita in the 2nd quarter valued at approximately $9,615,000. International Assets Investment Management LLC acquired a new position in shares of DaVita in the 3rd quarter valued at approximately $10,346,000. Finally, Hennessy Advisors Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at approximately $8,439,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 9,881 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the sale, the chief executive officer now owns 887,835 shares in the company, valued at $144,583,929.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. This trade represents a 36.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,086 shares of company stock worth $24,807,161 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

DaVita Trading Up 0.8 %

Shares of DaVita stock opened at $165.51 on Friday. DaVita Inc. has a 12-month low of $98.26 and a 12-month high of $168.50. The stock has a market cap of $13.57 billion, a P/E ratio of 17.85, a P/E/G ratio of 0.89 and a beta of 0.89. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The business’s 50 day moving average is $158.31 and its 200-day moving average is $148.29.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on DVA shares. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. Finally, Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.